Analyst Ratings for Acrivon Therapeutics

Loading...
Loading...

Analysts have provided the following ratings for Acrivon Therapeutics ACRV within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 1 0 0 0
Last 30D 0 1 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 2 0 0 0 0

These 4 analysts have an average price target of $23.5 versus the current price of Acrivon Therapeutics at $5.4, implying upside.

Below is a summary of how these 4 analysts rated Acrivon Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has decreased by 6.0% from the previous average price target of $25.00.

Stay up to date on Acrivon Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...